Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine*

Corea, L; Cardoni, Ondina; Fogari, Roberto; Innocenti, P.; Porcellati, Carlo; Provvidenza, M.; Meilenbrock, Susanne; Sullivan, John; Bodin, F.

doi:10.1016/s0009-9236(96)90061-2

Cited by 117 publications

(48 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 The present study sought to assess the antihypertensive efficacy and goal BP attainment rate with the recommended starting dose of olmesartan medoxomil, compared with that of the most widely prescribed antihypertensive agent, amlodipine. Although other ARBs have been compared with amlodipine in clinical trials, [20][21][22][23] the studies focused primarily on the absolute reduction in BP between the two agents and not on their ability to achieve a specific BP goal. Further, our study utilized ABPM and assessed the efficacy of these agents in attaining the rigorous control rates of SBP o130 mmHg and DBP o85 mmHg, thus providing robust data with which to evaluate the comparative efficacy of olmesartan medoxomil and amlodipine.…”

Section: Discussionmentioning

confidence: 99%

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension

Chrysant

Marbury

Robinson³

2003

J Hum Hypertens

View full text Add to dashboard Cite

The antihypertensive efficacy of the angiotensin II receptor blocker olmesartan medoxomil has been shown to compare favourably with that of other antihypertensive agents. This randomized, double-blind study compared the antihypertensive efficacy of the starting dose of olmesartan medoxomil with that of the calcium channel blocker amlodipine besylate (amlodipine) in subjects with mild-to-moderate hypertension. Following a 4-week, single-blind, placebo run-in period, 440 subjects aged X18 years were randomized to the starting dose of olmesartan medoxomil (20 mg/day), amlodipine (5 mg/day), or placebo for 8 weeks. Subjects were evaluated by 24-h ambulatory blood pressure monitoring (ABPM) and by seated cuff blood pressure (BP) measurements at trough. The primary end point was the change from baseline in mean 24-h diastolic blood pressure (DBP) by ABPM at Week 8. Secondary end points included change from baseline in mean 24-h ambulatory systolic blood pressure (SBP) at 8 weeks, change from baseline in mean seated trough cuff DBP and SBP measurements, and response and control rates for DBP o90 and o85 mmHg. Control rates for SBP o140 and o130 mmHg were also calculated. Olmesartan medoxomil and amlodipine produced significantly greater reductions in ambulatory and seated DBP and SBP compared with placebo. Mean reductions in ambulatory and seated BP were similar between the two active agents; however, in the olmesartan medoxomil group, significantly more patients achieved the SBP goal of o130 mmHg and the DBP goal of o85 mmHg. Both drugs were well tolerated at the recommended starting dose. Although amlodipine was associated with a higher incidence of oedema, this did not reach statistical significance. Olmesartan medoxomil is an effective antihypertensive agent, with BPlowering efficacy at the starting dose similar to that of amlodipine, and is associated with more patients achieving the rigorous BP goals of SBP o130 mmHg and DBP o85 mmHg.

show abstract

Section: Discussionmentioning

confidence: 99%

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension

Chrysant

Marbury

Robinson³

2003

J Hum Hypertens

View full text Add to dashboard Cite

show abstract

“…9 -11 Although all the major antihypertensive drug classes demonstrate comparable efficacy in blood pressure lowering, differences have been observed among agents in adverse-event profiles and longterm tolerability characteristics. For example, clinical trial data [12][13][14][15][16][17] and observational investigations 18 -24 indicate that angiotensin II type 1 receptor blockers (ARBs) have fewer adverse events, improved long-term tolerability profiles, and higher adherence rates relative to other classes of antihypertensive drugs, including angiotensinconverting enzyme (ACE) inhibitors, calcium channel blockers (CCBs), beta-blockers, and diuretics. Some of the previous observational studies of adherence to different antihypertensive drugs did not include ARBs, 20 included much smaller number of patients treated with losartan (the first ARB) than with other drug classes, 19,21 or demonstrated significant inhomogeneity across different ARBs.…”

mentioning

confidence: 99%

Persistence, Adherence, and Risk of Discontinuation Associated with Commonly Prescribed Antihypertensive Drug Monotherapies

Elliott¹,

Plauschinat²,

Skrepnek³

et al. 2007

The Journal of the American Board of Family Medicine

123

View full text Add to dashboard Cite

Measurements: Drug utilization following initiation. Cox proportional hazards regression models controlled for demographics, case-mix, and concomitant treatments.Results: Records for 60,685 subjects were included: HCTZ (n ‫؍‬ 18,713), amlodipine (n ‫؍‬ 11,520), lisinopril (n ‫؍‬ 21,138), or valsartan (n ‫؍‬ 9314). Over 1 year, 31% to 44% of subjects utilized no treatment for at least 60 days. Medication possession ratio (MPR) and adherence measures ranged from 73% to 90%. Valsartan was associated with significantly (P < .001) more favorable measures of persistence, length of therapy, time to discontinuation, MPR, and risk of discontinuation, compared with HCTZ, amlodipine, or lisinopril. The risk of discontinuation was 53%, 32%, and 14% greater for HCTZ, amlodipine, and lisinopril, respectively, versus valsartan (all comparisons P < .001). Conclusion: Among antihypertensive agents studied, valsartan was associated with the most favorable utilization patterns. Health care providers and systems should evaluate the use of antihypertensive drugs within their populations to identify and manage treatment discontinuation. (J Am Board Fam Med 2007;20:72-80.)Hypertension is a common and eminently treatable risk factor for major cardiovascular events, including coronary heart disease and stroke.1 Cardiovascular disease is the leading cause of morbidity and mortality in developed nations, 2 and is expected to increase in worldwide importance during the next 20 to 50 years. 3 The prevalence of hypertension seems to be increasing in both developed nations, where it currently affects approximately 1 in 3 adults, 4 and in developing countries. 5Meta-analyses and meta-regression analyses of clinical trials in hypertension have reported that pharmacologic drug therapy significantly reduces cardiovascular events, which is largely attributable This article was externally peer reviewed.

show abstract

“…Valsartan is an ARB that is highly selective for angiotensin II type 1 receptors, and its BP-lowering effect is sustained for 24 h after a single oral administration (14)(15)(16). In addition, its effect on BP is the same as those of other antihypertensive agents, including Ca antagonists, angiotensin converting enzyme inhibitors (ACEIs), and others (17,18). ARBs have recently become first-line agents for the treatment of hypertensive patients because they are associated with a lower rate of occurrence of adverse reactions than ACEIs and Ca antagonists.…”

Section: Introductionmentioning

confidence: 99%

Valsartan in Elderly Isolated Systolic Hypertension (VALISH) Study: Rationale and Design

et al. 2004

View full text Add to dashboard Cite

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine*

Cited by 117 publications

References 12 publications

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension

Persistence, Adherence, and Risk of Discontinuation Associated with Commonly Prescribed Antihypertensive Drug Monotherapies

Valsartan in Elderly Isolated Systolic Hypertension (VALISH) Study: Rationale and Design

Contact Info

Product

Resources

About